Opportunity Information: Apply for PAS 10 151
Apply for PAS 10 151
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Grants for Alzheimers Disease Drug Discovery (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Mar 22, 2010 and posted on Mar 22, 2010.
- Applicants must submit their applications by May 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) State governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Grants for Alzheimers Disease Drug Discovery (R21)" (Funding Opportunity Number PAS 10-151) is a discretionary grant program focused on pushing forward early-stage drug discovery efforts for Alzheimers disease (AD). Its central aim is to help generate new and effective therapies that can treat AD, slow or delay its progression, or prevent it altogether. In addition to Alzheimers disease itself, the announcement also explicitly includes mild cognitive impairment (MCI) and age-related cognitive decline, reflecting an interest in interventions that may work across the continuum from early or prodromal impairment through established dementia.
The scientific scope is centered on exploratory and developmental research that supports the first steps of discovering and validating therapeutic ideas. The FOA encourages studies that identify, optimize, and test potential treatments, including disease-modifying approaches as well as therapies aimed at improving the cognitive symptoms and the neuropsychiatric or behavioral symptoms that commonly accompany AD. A key point is that applications are welcome whether they focus on well-established targets or propose newer, less conventional targets, as long as the work is positioned to move the field toward promising therapeutic candidates. The emphasis is on innovation and effectiveness rather than incremental work, and on building a foundation that could enable later-stage development.
The program uses the NIH Exploratory/Developmental grant mechanism (R21). This mechanism is generally intended to support high-risk, high-reward projects at a relatively early stage, where preliminary data may be limited but the potential impact could be significant. Within this FOA, the R21 format is used to encourage the kinds of proof-of-concept, feasibility, and early validation studies that are often needed before larger, more definitive development programs can be justified.
In terms of funding levels, the listing provides an award ceiling of $200,000, and it notes that both the size and duration of awards may vary depending on the nature and scope of proposed projects. The FOA does not promise a fixed number of awards; instead, the total number and total dollars awarded depend on the quality of the applications received, along with their budgets, timelines, and scientific merit. There is no cost sharing or matching requirement, which means applicants are not required to contribute additional non-federal funds to qualify.
Eligibility is broad and is designed to include a wide range of organizations that can contribute to AD drug discovery. Eligible applicants include for-profit organizations (including small businesses and other for-profits), nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, and multiple levels of government (state, county, city/township, special district), as well as public housing authorities and tribal governments and organizations. The eligibility section also highlights inclusion of entities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations) and regional organizations. The sponsoring agency is the National Institutes of Health, and the opportunity is categorized under CFDA 93.866 (Aging Research), aligning it with broader federal investments in aging and neurodegenerative disease research.
Administratively, the opportunity was posted and created on March 22, 2010. The original and final closing date listed is May 7, 2013, with an archive date of June 7, 2013, indicating this specific announcement is no longer active but remains part of the public record. The full announcement was hosted on the NIH grants website (link provided in the source text), and the contact listed for access or linking issues is the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV).
Overall, this FOA was designed as an on-ramp for innovative Alzheimers therapeutic discovery, supporting early experiments and development steps that could yield credible candidates or approaches for later-stage testing, while explicitly positioning the program as complementary to, rather than competitive with, pharmaceutical industry drug development pipelines.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Grants for Alzheimers Disease Drug Discovery (R21)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAS 10-151.
Which federal agency sponsors this program?
The sponsoring agency is the National Institutes of Health (NIH).
What type of grant mechanism does this program use?
This program uses the NIH Exploratory/Developmental grant mechanism (R21).
What is the main purpose of this FOA?
The central aim is to advance early-stage drug discovery efforts for Alzheimers disease (AD) by helping generate new and effective therapies that can treat AD, slow or delay its progression, or prevent it.
Does the scope include conditions beyond Alzheimers disease?
Yes. In addition to Alzheimers disease, the announcement explicitly includes mild cognitive impairment (MCI) and age-related cognitive decline.
What stage of research is this FOA intended to support?
It is centered on exploratory and developmental research that supports early steps in discovering and validating therapeutic ideas, including proof-of-concept, feasibility, and early validation studies.
Is this funding intended for high-risk, high-reward projects?
Yes. The R21 mechanism is generally intended to support high-risk, high-reward projects at a relatively early stage, where preliminary data may be limited but potential impact could be significant.
What kinds of therapeutic approaches are encouraged?
The FOA encourages studies that identify, optimize, and test potential treatments, including disease-modifying approaches as well as therapies aimed at improving cognitive symptoms and neuropsychiatric or behavioral symptoms associated with AD.
Are applications limited to well-established drug targets?
No. Applications are welcome whether they focus on well-established targets or propose newer, less conventional targets, as long as the work is positioned to move toward promising therapeutic candidates.
Does the FOA prioritize innovation over incremental work?
Yes. The emphasis is on innovation and effectiveness rather than incremental work, and on building a foundation that could enable later-stage development.
What is the maximum award amount listed for this opportunity?
The listing provides an award ceiling of $200,000.
Are the award size and project duration fixed?
No. The size and duration of awards may vary depending on the nature and scope of proposed projects.
Is there a guaranteed number of awards?
No. The FOA does not promise a fixed number of awards. The total number and total dollars awarded depend on the quality of applications received, along with their budgets, timelines, and scientific merit.
Is cost sharing or matching required to apply?
No. There is no cost sharing or matching requirement; applicants are not required to contribute additional non-federal funds to qualify.
What types of organizations are eligible to apply?
Eligibility is broad and includes for-profit organizations (including small businesses and other for-profits), nonprofit organizations (with or without 501(c)(3) status), public and private institutions of higher education, and various levels of government (state, county, city/township, special district), as well as public housing authorities and tribal governments and organizations.
Are small businesses and other for-profit entities eligible?
Yes. For-profit organizations, including small businesses and other for-profits, are explicitly listed as eligible applicants.
Are nonprofits required to have 501(c)(3) status to be eligible?
No. Nonprofit organizations are eligible with or without 501(c)(3) status.
Are colleges and universities eligible?
Yes. Public and private institutions of higher education are eligible.
Are specific institution types (like HBCUs or Hispanic-serving institutions) mentioned as eligible?
Yes. The eligibility section highlights inclusion of Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian Serving Institutions.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are included among eligible entities.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are listed among eligible entities.
Can non-U.S. (foreign) organizations apply?
Yes. The eligibility section includes non-U.S. entities (foreign organizations) and regional organizations.
What CFDA number is associated with this opportunity?
This opportunity is categorized under CFDA 93.866 (Aging Research).
When was this opportunity posted?
It was posted and created on March 22, 2010.
What were the closing dates for applications?
The original and final closing date listed is May 7, 2013.
Is this FOA currently active?
No. The archive date is June 7, 2013, indicating this specific announcement is no longer active and remains available as part of the public record.
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants website (as indicated in the source information).
Who is the contact for access or linking issues related to the announcement?
The contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
How does this FOA relate to pharmaceutical industry drug development?
The FOA is described as complementary to, rather than competitive with, pharmaceutical industry drug development pipelines, supporting early experiments and development steps that could enable later-stage testing.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Pagan Island Snail Surveys
Previous opportunity: FY 2010 Health Risks, Safety Incidents, and Traumatic Related Events (Union Pacific Railroad)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAS 10 151
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAS 10 151) also looked into and applied for these:
| Funding Opportunity |
|---|
| National HIV Program Apply for HHS 2010 IHS OCPS HIV 0001 Funding Number: HHS 2010 IHS OCPS HIV 0001 Agency: Indian Health Service Category: Health Funding Amount: $90,000 |
| FY10 FP Clinical Training FOA Apply for PA FPT 10 001 Funding Number: PA FPT 10 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $700,000 |
| Geriatric Training Program for Physicians, Dentists, And Behavioral And Mental Health Professions Apply for HRSA 10 044 Funding Number: HRSA 10 044 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Combination HIV Prevention for the General Population of Adults and Youth, including Persons Living with HIV (PLH), in Mozambique Apply for RFA 656 10 005 Funding Number: RFA 656 10 005 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $26,000,000 |
| Puerto Rican Cultural Center, Vida/SIDA Program, Apply for CDC RFA PS10 10177E Funding Number: CDC RFA PS10 10177E Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| National Environmental Public Health Tracking Program National Association for Public Health Statistics and Information Systems Apply for CDC RFA EH10 1004 Funding Number: CDC RFA EH10 1004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $125,000 |
| NIBIB Biomedical Technology Resource Centers (P41) Apply for PAR 10 153 Funding Number: PAR 10 153 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Population based surveillance for Deep Vein Thrombosis and Pulmonary Embolism Apply for CDC RFA DD10 1016 Funding Number: CDC RFA DD10 1016 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Geriatric Education Centers Apply for HRSA 10 091 Funding Number: HRSA 10 091 Agency: Health Resources and Services Administration Category: Health Funding Amount: $400,000 |
| Improving Implementation of Programs for Care Treatment of HIV/AIDS in the Republic of Mozambique under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS10 1081 Funding Number: CDC RFA PS10 1081 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Programs for Pool and Spa Safety Apply for CDC RFA CE10 1002 Funding Number: CDC RFA CE10 1002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Research Opportunities on Spasmodic Dysphonia (R21) Apply for PA 10 156 Funding Number: PA 10 156 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research Opportunities on Spasmodic Dysphonia (R01) Apply for PA 10 157 Funding Number: PA 10 157 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Career Enhancement Award for Established Investigators (K18) Apply for PAR 10 162 Funding Number: PAR 10 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Adolescent Health Earmarks 2010 Apply for CDC RFA DP10 1021E Funding Number: CDC RFA DP10 1021E Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) Apply for PAR 10 161 Funding Number: PAR 10 161 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Research Scientist Development Award (K01) Apply for PAR 10 132 Funding Number: PAR 10 132 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| State based Surveillance for Hemoglobinopathies Apply for CDC RFA DD10 1017 Funding Number: CDC RFA DD10 1017 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Health Care and Other Facilities Apply for HRSA 10 041 Funding Number: HRSA 10 041 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| State Approaches to Estimating Incidence and Prevalence of Lupus Apply for CDC RFA DP10 1011 Funding Number: CDC RFA DP10 1011 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAS 10 151", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.